Cell-Based Assays in Drug Development From Cells to Cures Beyond Traditional Methods: Cell-Based Assays Refine Drug Discovery

Cell-Based Assay Market to reach over USD 32.02 billion by the year 2031 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell-Based Assay Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments & Software, And Services), Application (Drug Screening, Basic Research, Predictive Toxicology), Technology (Flow Cytometry, Automated Handling, High Throughput Screening, High Content Screening), And End-User (Pharmaceutical & Biopharmaceutical Companies, CROs, Academic Research)- Market Outlook And Industry Analysis 2031"

The Global Cell-Based Assay Market is estimated to reach over USD 32.02 billion by 2031, exhibiting a CAGR of 7.72% during the forecast period.

Get a free sample copy of the reporthttps://www.insightaceanalytic.com/request-sample/1793

Chronic Disease Surge Fuels Growth in Cell-Based Assay Market
The cell-based assay market is experiencing significant growth driven by the rising prevalence of chronic illnesses and lifestyle disorders. Here's a closer look at the key factors:
• Escalating Cancer Rates: A December 2020 study by the International Agency for Research on Cancer (IARC) revealed a staggering 19.3 million existing cancer cases globally. Furthermore, the IARC projects an additional 27.5 million cases by 2040. This increasing global cancer burden will fuel demand for effective therapies, consequently driving the cell-based assay market. Cell-based assays play a crucial role in drug discovery for cancer treatment.

• Burden of Cardiovascular Disease: Data from the European Heart Network (2021) highlights the immense burden of cardiovascular disease, with over 60 million existing cases in the European Union alone and a staggering 13 million new cases identified annually. This rise in cardiovascular illnesses translates to a growing need for cell-based assays in drug discovery efforts, propelling market expansion.

In conclusion, the alarming rise of chronic diseases like cancer and cardiovascular illness is creating a strong demand for efficient therapies. Cell-based assays play a vital role in drug discovery for these conditions, positioning the cell-based assay market for significant growth in the coming years.

Additionally, a rise in cell-based applications for drug discovery and a rise in technological developments in cell-based assay methodologies have led to a significant increase in the demand for cell-based assays.

List of Prominent Players in the Cell-Based Assay Market:

• PerkinElmer, Inc.
• Eurofins DiscoverX Products
• Cell Signaling Technology, Inc.
• Charles River Laboratories International, Inc.
• Laboratory Corporation of America Holdings
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Corning Incorporated
• Lonza Group AG
• Agilent Technologies, Inc.
• Promega Corporation

Market Dynamics:
Drivers-
Unlike biochemical experiments, they provide constant tissue-specific responses in a physiologically realistic milieu. The pharmaceutical and biotechnology companies are also utilizing cell-based assays as part of their lead identification and optimization processes for drug development, which is the main reason fueling this market's expansion.

Additionally, the likelihood of disease outbreaks (such as COVID-19 and swine flu) increasing as well as an increase in research activities are predicted to drive market expansion. The market's expansion is additionally anticipated to be tempered by the cheap costs of labor and raw materials as well as the rising number of CROs offering drug discovery services.

Challenges:
The usage of these pricey methods has significantly raised the overall cost of producing biopharmaceuticals. Due to low adaption, the expensive instrumentation will result in a lower return on investment (ROI), which is anticipated to impede market expansion. The market for cell-based assays is also predicted to have complications throughout the forecast period due to a lack of qualified workers.

Regional Trends:
Due to the developed healthcare industry and widespread use of cell-based assays, North America now holds the largest market share globally. Chronic diseases like cancer, osteoarthritis, and diabetes are becoming more common in the United States, which is boosting demand for cell-based assays for innovative drug discoveries and contributing to the expansion of this market. For example, according to the

American Cancer Society's Cancer Facts & Figures 2022 data, there will be an anticipated 1.9 million new cancer cases identified and 609,360 cancer deaths in the United States. Similarly to this, the American Heart Association stated in January 2022 that someone would experience a myocardial infarction in the United States every 40 seconds on average. The prevalence of chronic diseases in the American population is predicted to fuel market expansion over the course of the forecast period.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1793

Recent Developments:
• In August 2022, Cytotoxicity testing, biocompatibility assays, and other cell-based assay services were introduced by Life Net Health LifeSciences.
• In May 2022, The Aquios STEM system was introduced by Beckman Coulter Life Sciences to offer a fresh approach to stem cell investigation. With fewer manual and error-prone stages, the turnaround time is reduced dramatically.

Segmentation of Cell-Based Assay Market-
By Product-
• Consumables
o Reagents
o Assay Kits
o Microplates
o Cell Lines
o Probes and Labels
o Other Consumables
• Instruments and Software
• Services

By Application-
• Drug Screening
• Basic Research
• Predictive Toxicology
• Other Applications (Other Industries, Cell and Gene therapy, among others)

By Technology-
• Flow Cytometry
• Automated Handling
• High Throughput Screening
• High Content Screening
• Other Technologies (Label-Free Detection, Image Cytometry, among others

By End User-
• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Other End Users (Government Organizations)

By Region-
North America-
• The US
• Canada
• Mexico

Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/report/cell-based-assay-market/1793

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.